64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Recruiting now · Phase 1/Phase 2
Conditions studied: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
In brief
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Key facts
- Study ID
- NCT06298916
- Run by
- Lantheus Medical Imaging
- People needed
- 26
- Starts
- 2025-08-01
- Expected to finish
- 2026-04-01
- Last updated by the study team
- 2025-08-12
Who can join
Age: 15 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California, United States (enrolling)
- Stanford Hospital & Clinics — Stanford, California, United States (enrolling)
- BAMF Health, Inc. — Grand Rapids, Michigan, United States (enrolling)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.